Anti-counterfeiting measures for glass articles
A glass container including a body having a delamination factor less than or equal to 10 and at least one marking is described. The body has an inner surface, an outer surface, and a wall thickness extending between the outer surface and the inner surface. The marking is located within the wall thickness. In particular, the marking is a portion of the body having a refractive index that differs from a refractive index of an unmarked portion of the body. Methods of forming the marking within the body are also described.
1. A pharmaceutical package comprising:
a glass body having a delamination factor of less than or equal to 10, the glass body having an inner surface, an outer surface, and a wall thickness extending between the outer surface and the inner surface, wherein the glass body is ion exchanged and comprises a compressively stressed layer extending from the outer surface of the glass body into the wall thickness, the compressively stressed layer having a surface compressive stress greater than or equal to 150 MPa; and
at least one marking comprising a first marking comprising a photonic microstructure within the wall thickness, the marking comprising a portion of the body having a refractive index that differs from a refractive index of an unmarked portion of the body; wherein:
the at least one marking is not within the compressively stressed layer and does not impact a strength of the glass body, a damage resistance of the glass body, or the delamination factor of the glass body; and
the at least one marking further comprises a second marking comprising a fluorescence attributable to a composition of the pharmaceutical package and a low coefficient of friction coating, wherein a portion of the coating has been selectively removed to form the second marking.
2. The pharmaceutical package of claim 1 , wherein the at least one marking enables the pharmaceutical package to be traced through a manufacturing process, a filling process, or in a field of use.
3. The pharmaceutical package of claim 1 , wherein the glass body is formed from an alkali-aluminosilicate glass composition.
4. The pharmaceutical package of claim 3 , wherein the alkali-aluminosilicate glass composition is substantially free from boron and compounds containing boron.
5. The pharmaceutical package of claim 1 , wherein the at least one marking is a covert marking.
6. The pharmaceutical package of claim 1 , wherein the first marking is within a middle 80% of the wall thickness.
7. The pharmaceutical package of claim 1 , wherein the refractive index of the first marking differs from the refractive index of the unmarked portion of the body by from about 0.3% to about 0.5%.
8. The pharmaceutical package of claim 1 , wherein the first marking is formed by a femtosecond laser having a pulse energy of less than 10 nJ.
9. The pharmaceutical package of claim 1 , wherein the first marking is formed by focusing a laser beam with an aspherical lens with a numerical aperture in a range of from 0.3 to 0.7.